PATENT CLAIM ANALYSIS

Application Number: 15991382
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "254090"]

Abstract:
Compositions and methods for treating hyperemia and symptoms in pinguecula and pseudopteryigium are disclosed. The methods include administration of a multikinase inhibitor, an antimetabolite or a combination thereof to patients in need thereof.

Claim (Index 12):
The method of  claim 1 , wherein the the multikinase inhibitor is selected from the group consisting of Afatinib, Amuvatinib, Axitinib, Cabozantinib, Canertinib, Cediranib, Ceritinib, Crenolanib, Crizotinib, Dabrafenib, Dacomitinib, Dasatinib, Erlotinib, Foretinib, Gefitinib, Golvatinib, Ibrutinib, Icotinib, Idelalisib, Imatinib, Lapatinib, Lenvatinib, Neratinib, Nilotinib, Nintedanib, Palbociclib, Pazopanib, Ponatinib, Quizartinib, Regorafenib, Ruxolitinib, Sorafenib, Sunitinib, Tandutinib, Tivantinib, Tivozanib, Trametinib, Vandetanib, Vatalanib, and Vemurafenib.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 93.0
- Lexical Diversity: 1.24138
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15991698', '15474620', '15375820', '15700735', '12463279']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8395850239341583
- 35 USC 102 Novelty (BERT): 0.641445726785101
- Combined Prediction Score: 0.8197710942192526
- Mean Citation Score: 454.514394
- Max Citation Score: 605.0357700000002
- Similarity Product: 586.5544137230856

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test